key: cord-0920811-2ekpxpzj authors: Çölkesen, Fatih; Poyraz, Necdet; Arslan, Şevket; Yılmaz, Pınar Diydem; Kepenek Kurt, Esma; Korkmaz, Celalettin; Yıldız, Eray; Çölkesen, Fatma; Aytekin, Gökhan; Keleş, Sevgi; Reisli, İsmail title: An association between immune status and chest CT scores in COVID‐19 patients date: 2021-09-12 journal: Int J Clin Pract DOI: 10.1111/ijcp.14767 sha: 7712a95c86e01812bb8414006a98a3866ec9f54c doc_id: 920811 cord_uid: 2ekpxpzj BACKGROUND: The characteristic features of the immune responses of COVID‐19 patients and how they reflect lung involvement have not been clearly elucidated. AIM: The aim of this study was to examine the immune status and the correlations thereof with chest CT scores and lung involvement of patients with COVID‐19. METHODS: In this retrospective and single‐center study, 72 patients with laboratory‐confirmed COVID‐19 were recruited. The counts of peripheral lymphocyte subsets (CD3(+) T cells, CD4(+) T cells, CD8(+) T cells, CD19(+) B cells and CD16(+) 56(+) NK cells) and those of serum immunoglobulins (IgA, IgG, IgM) were measured and their associations with chest CT scores analysed. RESULTS: The proportions of lymphopenia in patients with extensive lung involvement were twice that in the general study population. In the severe disease group, the levels of total lymphocytes, T cells, B cells, NK cells; and serum IgA levels, were significantly lower than in the mild disease group (all P < .05). We found that the numbers of lymphocyte subsets and the IgA level negatively correlated with the chest CT scores. On multivariate regression analysis, pretreatment decreases in total lymphocytes, CD3(+) T cells, CD4(+) T cells, and CD19(+) B cells, and serum IgA levels, were independent predictors of severe lung involvement. CONCLUSIONS: The cell numbers of peripheral lymphocyte subsets and the serum IgA level were negatively correlated with the chest CT scores in COVID‐19 patients. These parameters tended to independently predict severe lung involvement in such patients. The coronavirus disease 2019 (COVID- 19) pandemic, which first emerged in December 2019 in pneumonia patients in Wuhan, China, and then spread worldwide, has caused over 150 million confirmed cases and more than 3 million deaths to date. 1, 2 The clinical course of COVID-19 disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may vary from asymptomatic to severe; the latter patients may require mechanical ventilation. 3 The incidence of severe COVID-19 disease is between 15.7% to 26.1%. The criteria include clinical tachypnoea and hypoxia, as well as an extent of lung infiltration >50%. 4 Reverse transcription-polymerase chain reaction (RT-PCR), which is the main test used to diagnose COVID-19, has certain limitations in terms of sample collection and transport, and kit performance. The sensitivity is relatively low (60%-71%). Chest CT is routinely used to image and diagnose all types of pneumonia, affording high sensitivity (97%) when (rapidly) diagnosing COVID-19 disease. 5 Severe COVID-19 patients have more extensive lung involvement than asymptomatic or mild patients. In addition, there are significant positive correlations between COVID 19 severity evident on chest CT and dyspnoea and deteriorating gas exchange. 4, 6 Approximately 20% of patients with COVID-19 develop acute respiratory distress syndrome (ARDS), the clinical course of which exhibits uncontrolled immune system activation, excessive cytokine release and multi-organ failure. 7, 8 Increased serum levels of proinflammatory cytokines are associated with pulmonary inflammation and extensive lung injury. 9 Lymphocyte subsets (CD4 + T important roles in the immune response. Changes in lymphocyte subsets vary by the type of viral infection and viral pathogenic mechanisms. 10 However, the characteristic features of the immune response in patients with severe COVID-19 infections and their effects on the clinical findings remain unclear. Some studies have suggested that immune system overactivation plays a role in the immunopathology 11 ; others have stated that loss or dysfunction of immune cells may be responsible. 12 In this study, we examined the relationship between the severity of lung involvement and immune system factors (which vary widely among COVID-19 patients). We aimed to characterise immune status, which can illuminate the pathogenesis of COVID-19, and sought an early indicator of severe lung involvement in patients with COVID-19 infections. This retrospective cohort study was conducted in Necmettin Erbakan University Meram Medical Faculty Hospital, which is a large tertiary hospital. The study was approved by the local Ethics Committee of Necmettin Erbakan University Meram Faculty of Medicine (decision no. 2020/2620); the study adhered to all relevant tenets of the Declaration of Helsinki (1975). Among patients who were hospitalised with a diagnosis of COVID-19 (laboratory-confirmed cases, detected by the SARS-CoV-2 RNA molecular method) between March 10, 2020, and June 08, 2020, those who met the following inclusion criteria were accepted into the study: (a) Over 18 years of age; and, (c) A diagnosis of a structural lung disease (bronchiectasis, an interstitial lung disease, etc). A total of 117 patients were enrolled according to the inclusion criteria but 45 were excluded for the reasons as shown in Figure 1 . As a result, 72 confirmed COVID-19 patients were finally enrolled in the study. • The severity of lung involvement varies considerably among patients in the acute phase of COVID-19. • Severe COVID-19 patients have more extensive lung involvement than asymptomatic or mild patients. • The difference in the extent of lung involvement among COVID-19 patients and its relation to the patient's immune status during acute infection is poorly understood. • This is a pioneering study demonstrating a significant relationship between severe lung involvement and host immune status during the acute phase of COVID-19. • The cell numbers of peripheral lymphocyte subsets and the serum IgA levels were negatively correlated with the chest CT scores in COVID-19 patients. • These parameters tended to independently predict severe lung involvement in such patients. • Early evaluation of CT scores and immune parameters in COVID-19 patients is essential in determining severe patients. • Thus, the patient groups that need to be applied aggressive treatment modalities in the early stages may be determined, and a decrease in the morbidity and mortality rates because of COVID-19 may be achieved. We recorded age, gender, medical history, laboratory values, chest CT findings and disease severity assessments at the time of admission to our hospital, from electronic medical records. Patients with COVID-19 are considered to have severe illness if they exhibit an oxygen saturation (SpO2) <94% on room air at sea level, a respiratory rate >30 breaths/min, a ratio of the arterial partial pressure of oxygen to the fraction of inspired oxygen (PaO 2 / FiO 2 ) <300 mmHg, or lung infiltration >50%. 13 We investigated the relationship between the severity of lung involvement evident on chest CT and the numbers of total lymphocytes and those of various subgroups of peripheral lymphocytes (T-cells, B-cells, NK cells), and serum immunoglobulin levels (IgG, IgA and IgM) in COVID-19 patients. SARS-CoV-2 RNA was detected using the reverse transcriptionpolymerase chain reaction (RT-PCR) test; we combined nasopharyngeal and oropharyngeal swabs. RNA was isolated using the vNAT solution (Bioeksen, Istanbul, Turkey). A Rotor-Gene Q (Qiagen, Antwerp, Belgium) instrument and a Biospeedy SARS-CoV-2 RT-qPCR kit (Bioeksen) were used in all tests. The data were analysed using Rotor-Gene Q Software. Serum immunoglobulin levels were determined by nephelometric methods (Siemens BNII System, Erlangen, Germany). Samples of EDTA-anticoagulated peripheral blood (2 mL) were collected from all patients before initial treatment. All samples were tested within 6 hours of being obtained. CD3 + /CD4 + /CD8 + T cell, All chest CT examinations were performed using a Somatom Drive (Siemens Healthineers) scanner. Unenhanced CT scans were obtained from the bilateral apex to the base for all patients. The scanning parameters were as follows: Tube voltage, 120 kV; tube current-time product, 50-100 mAs; pitch, 0.6; matrix, 512 × 512; slice thickness, Severity scores were awarded to each of the five lung lobes: 0 for no involvement (0%), 1 for minimal involvement (1%-25%), 2 for mild involvement (26%-50%), 3 for moderate involvement (51%-75%) and 4 for advanced involvement (76%-100%). The total severity score was the sum of the scores of the five lobes. We categorised all patients into two groups according to their total chest CT scores (≤10 vs >10): Mild involvement and severe involvement (Figures 2 and 3 ). Continuous variables are presented as medians with interquartile ranges (IQRs), and categorical variables as numbers and percentages in each category. We used the Mann-Whitney U-test to evaluate continuous data and the chi-squared test to evaluate categorical data when comparing the mild and severe COVID-19 patients. Spearman's correlation test was used to assess the association between lymphocyte subset counts, serum immunoglobulin levels, and the chest CT scores. Univariate and multivariate logistic regression analyses were used to identify risk factors for severe lung involvement. All variables with P-values <.1 on univariate analysis were entered into forward, stepwise multivariate logistic regression analysis. The SPSS statistical package (ver. 22.0; IBM Corp., Armonk, NY, USA) and GraphPad Prism statistical software (ver. 8.0; GraphPad Software, San Diego, CA, USA) were used for all analyses. A P-value <.05 was considered statistically significant. We included 72 patients with COVID-19. The median age was 48 years (IQR, 38-65 years) and 33 (46%) were female. We found no between-gender difference in disease prognosis or the extent of pulmonary involvement (P = .396 and 0.280 respectively). Nineteen patients had severe disease, of whom 15 exhibited extensive lung involvement on chest CT (>50% lung involvement, CT score >10). The lymphopenia proportion was 32% (n = 23) in a general study population, 63% (n = 12) in patients with severe disease and 67% (n = 10) in those with extensive lung involvement. As shown in Table 1 , in patients with severe COVID-19, the total CT score, the creatinine, Ddimer and ferritin levels, the erythrocyte sedimentation rate (ESR), and the C-reactive protein (CRP) level were higher than in patients with mild COVID-19 (P = <0.001, 0.001, 0.003, 0.017, 0.039 and 0.001 respectively). We categorised 19 patients (26%) as severely ill on admission. These patients had significantly lower levels of total lymphocytes (P < .001), CD3 + T cells (P < .001), CD3 + CD4 + T cells (P < .001), CD3 + CD8 + T cells (P < .001), CD19 + B cells (P = .013) and CD16 + CD56 + NK cells (P = .024) than patients with mild COVID-19. The serum IgA levels were significantly lower in patients with severe compared with mild illness (P = .028). We found no between-group IgG or IgM difference (P = .157 and 0.922 respectively; Table 1 ). 52-year-old man with COVID-19 pneumonia. Axial CT images shows bilateral, multilobar, peripheral and central, patchy ground-glass opacities. COVID-19 chest CT severity score is "7" We found severe lung involvement on chest CT (>50% lung involvement, CT score >10) in 15 patients (21%). Compared with patients with mild lung involvement, the severe cases exhibited In the current study, the proportions of lymphopenia in patients with severe disease and extensive lung involvement were twice that in the general study population. In the severe disease group, the num- IgA levels, were significantly lower than in the mild disease group. Comparison of peripheral lymphocyte subset counts and serum immunoglobulin levels between patients with COVID-19 exhibiting mild (lung) involvement (MI) and severe involvement (SI) on chest CT. ***P < .001; **P < .01; ns, not significant We found that decreases in the numbers of total lymphocytes, the vast majority of lymphocyte subsets (except for NK cells), and lower IgA levels were associated with high COVID-19 chest CT scores and extensive lung involvement. Lymphocytes are vital in terms of maintaining immune system functionality. As observed in patients with immune system disor- in lymphocyte levels. 14 Similar to the findings of our study, it has been reported in previous studies that dramatic decreases in total lymphocyte counts were common in COVID-19 patients and were associated with the severity of chest CT findings and poor disease prognosis. It has been shown that COVID-19 patients with extensive lung involvement exhibit more severe decreases in lymphocyte levels, and a negative correlation was evident between lymphocyte counts and lesions in the lungs. 15 Antibodies play essential roles in the immune responses to viruses; patients with antibody-deficient diseases such as common variable immunodeficiency (CVID) are predisposed to viral infections. 35 IgA is the most abundant antibody in the body, being a critical component of the mucosal immunity defense against infectious agents that target the mucosa. 36 Ig A binds to both bacteria and viruses, preventing their adhesion to epithelial cells, thus contributing to the first-step immune response against various pathogens. 37 IgA is principally responsible for the mucosal immunity of the respiratory and gastrointestinal systems, which are the main routes of entry of SARS-CoV-2 and other pathogens. IgA can neutralise the virus by preventing SARS-CoV-2 from reaching and adhering to epithelial cells. 38 In COVID-19 patients with abnormally low IgA levels, the risk of pneumonia was 4-fold higher than that of other patients. 39 In one study investigating the relationship between the prevalence of selective immunoglobulin A deficiency (SIgAD) and the prevalence of COVID-19 in various countries worldwide, it was concluded that a strong positive correlation was evident. In Japan, where SIgAD is extremely rare, the frequency of infections by, and mortality from, SARS-CoV-2 is low. In the USA and other Western countries, where the frequency of SIgAD is much higher than in Japan, the infection and death rates from SARS-CoV-2 are higher than in Japan. 37 Our study had some limitations. Despite these limitations, we showed that the severity of lung involvement, which may vary considerably among patients in the acute phase of COVID-19, and thus the chest CT scores, were related to immune parameter measurements. To the best of our knowledge, very few studies on this subject have appeared. For patients with COVID-19, no prior study has examined the relationship between IgA levels and chest CT scores. In this respect, our study offers a new perspective; it may be possible to develop nasal vaccines that increase IgA levels in mucosal membranes, neutralising SARS-CoV-2 in mucosae before the virus enters the cell. The prevalence and prognosis of SARS-CoV-2 pneumonia vary considerably among individuals. We have shown that the prognosis and the severity of chest CT involvement in COVID-19 are related to the levels of immune cells. Interestingly, we found that the levels of B lymphocytes, IgA levels and T lymphocyte levels were negatively correlated with the chest CT scores. Also, the levels of total lymphocytes, CD3 + T cells, CD3 + CD4 + T cells, and CD19 + B cells and serum IgA levels, were lower than the normal ranges, and associated with severe lung involvement. Early evaluation of CT scores and immune parameters in COVID-19 patients is essential in determining severe patients. Thus, the patient groups that need to be applied aggressive treatment modalities in the early stages may be determined, and a decrease in the morbidity and mortality rates because of COVID-19 may be achieved. New treatment strategies that improve immune system cell numbers and functions should be considered, especially for severely COVID-19 patients. The authors thank all healthcare professionals working in the COVID-19 pandemic process and all scientists who have contributed to the diagnosis, treatment and management of the pandemic through clinical trials. All authors declare that they do not have a conflict of interest. What we know so far: COVID-19 current clinical knowledge and research Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications CT quantitative analysis and its relationship with clinical features for assessing the severity of patients with COVID-19 Chest CT features of COVID-19 in Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics Cytokine release syndrome in severe COVID-19 On the alert for cytokine storm: immunopathology in COVID-19 Clinical features of patients infected with 2019 novel coronavirus in Wuhan Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia Clinical characteristics of 82 cases of death from COVID-19 Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients Treatment Guidelines Imbalance between Th17 and regulatory T cells in patients with systemic lupus erythematosus combined EBV/CMV viraemia Relationship between chest CT manifestations and immune response in COVID-19 patients Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study Lymphocyte subset counts in COVID-19 patients: a meta-analysis The clinical course and its correlated immune status in COVID-19 pneumonia Lymphopenia in COVID-19: therapeutic opportunities Structural basis of assembly of the human T cell receptor-CD3 complex Adaptive immune responses to primary and secondary dengue virus infections Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19 Correlation between relative nasopharyngeal virus RNA load and lymphocyte count disease severity in patients with COVID-19 Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients Elevated exhaustion levels of NK and CD8 + T cells as indicators for progression and prognosis of COVID-19 disease Functional exhaustion of antiviral lymphocytes in COVID-19 patients Clinical and immunological features of severe and moderate coronavirus disease 2019 T-cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of coronavirus disease 2019 Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity A possible role for B cells in COVID-19?: lesson from patients with Agammaglobulinemia Influenza Pathogenesis and Control -Volume II Association between selective IgA deficiency and COVID-19 The role of IgA in COVID-19 Immune-related factors associated with pneumonia in 127 children with coronavirus disease 2019 in Wuhan An association between immune status and chest CT scores in COVID-19 patients